Navigation Links
New Pharmaxis Board Appointment
Date:4/6/2009

SYDNEY, April 6 /PRNewswire-Asia/ -- Pharmaceutical company Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced the appointment of the U.S. life science investment manager Richard van den Broek to its Board of Directors.

Mr van den Broek is founder and managing partner of HSMR Advisors LLC, a U.S. based fund manager with an investment emphasis on small and mid-cap biotech public companies. HSMR Advisors has held a position on the Pharmaxis share register since 2005.

During his career Mr van den Broek has worked on both the buy and sell side of the funds management industry holding senior positions at Cooper Hill Partners, Hambrecht & Quist (H&Q), Merrill Lynch and Oppenheimer & Co.

"Richard has been an engaged investor for a number of years and has great insight into the life science industry and the U.S. capital markets," said Pharmaxis Chief Executive Officer, Dr Alan Robertson. "Our shareholders will benefit from his skills and experience."

In accepting the board position Mr van den Broek said: "Pharmaxis holds enormous promise and I look forward to being part of an exciting company at a key point in its development as a global provider of innovative medicines.

I am very much looking forward to working with the Pharmaxis Board."

Mr van den Broek is a Chartered Financial Analyst, and is a graduate of Harvard University.

    For information on all Pharmaxis Board members, go to:
   http://www.pharmaxis.com.au/about-us/our-people/our-people_home.cfm

Forward-Looking Statements

The statements contained in this media release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential for Aridol and/or Bronchitol. All forward-looking statements included in this media release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. We cannot guarantee that any product candidate will receive FDA or other regulatory approval or that we will seek any such approval. Factors that could cause or contribute to such differences include, but are not limited to, factors discussed in the "Risk Factors and Other Uncertainties" section of our Form 20-F lodged with the U.S. Securities and Exchange Commission.

    CONTACT:

     Alan Robertson -- Chief Executive Officer
     Tel:   +61-2-9454-7200
     Email: alan.robertson@pharmaxis.com.au

    RELEASED THROUGH:
     Australia:
     Felicity Moffatt
     Tel:   +61-418-677-701
     Email: felicity.moffatt@pharmaxis.com.au

    United States:
     Brandon Lewis, Trout Group
     Tel:   +1-646-378-2915
     Email: blewis@troutgroup.com

'/>"/>
SOURCE Pharmaxis Ltd
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Pharmaxis Investor Conference Call
2. Pharmaxis Appoints French Distributor for Aridol(TM)
3. Pharmaxis Builds Senior Management Team
4. Pharmaxis Investor Conference Call
5. Pharmaxis Aridol Approved for Sale in Switzerland
6. Pharmaxis Investor Conference Call
7. Pharmaxis Research Programs Highlighted at European Respiratory Society Congress
8. New Pharmaxis Board Appointment
9. Pharmaxis Aridol Authorised for Sale in Germany
10. Pharmaxis First Steps into China
11. Pharmaxis to Apply to Market Bronchitol in Australia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, one ... of their brand, UP4™ Probiotics, into Target stores nationwide. The company, which has ... add Target to its list of well-respected retailers. This list includes such fine ...
(Date:6/23/2016)... 2016 Houston Methodist Willowbrook Hospital has ... Association to serve as their official health care ... Willowbrook will provide sponsorship support, athletic training services, ... coaches, volunteers, athletes and families. "We ... Association and to bring Houston Methodist quality services ...
(Date:6/23/2016)... FRANCISCO , June 23, 2016   EpiBiome ... has secured $1 million in debt financing from Silicon ... ramp up automation and to advance its drug development ... its new facility. "SVB has been an ... beyond the services a traditional bank would provide," said ...
Breaking Biology Technology:
(Date:4/26/2016)... DUBLIN , April 27, 2016 ... of the  "Global Multi-modal Biometrics Market 2016-2020"  report ... ) , The analysts forecast ... a CAGR of 15.49% during the period 2016-2020.  ... a number of sectors such as the healthcare, ...
(Date:4/14/2016)... 2016 BioCatch ™, the ... announced the appointment of Eyal Goldwerger as ... Goldwerger,s leadership appointment comes at a time of ... deployment of its platform at several of the world,s ... discerns unique cognitive and physiological factors, is a winner ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
Breaking Biology News(10 mins):